| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, Hampshire, United Kingdom;
Department of Medical Specialties, Southampton General Hospital, Southampton, Hampshire, United Kingdom; and
Xenova Group plc, Slough, Berkshire, United Kingdom
The endothelium is the primary barrier to leukocyte recruitment at sites of inflammation. Neutrophil recruitment is directed by transendothelial gradients of IL-8 that, in vivo, are bound to the endothelial cell surface. We have investigated the identity and function of the binding site(s) in an in vitro model of neutrophil transendothelial migration. In endothelial culture supernatants, IL-8 was detected in a trimolecular complex with heparan sulfate and syndecan-1. Constitutive shedding of IL-8 in this form was increased in the presence of a neutralizing Ab to plasminogen activator inhibitor-1 (PAI-1), indicating a role for endothelial plasminogen activator in the shedding of IL-8. Increased shedding of IL-8/heparan sulfate/syndecan-1 complexes was accompanied by inhibition of neutrophil transendothelial migration, and aprotinin, a potent plasmin inhibitor, reversed this inhibition. Platelets, added as an exogenous source of PAI-1, had no effect on shedding of the complexes or neutrophil migration. Our results indicate that IL-8 is immobilized on the endothelial cell surface through binding to syndecan-1 ectodomains, and that plasmin, generated by endothelial plasminogen activator, induces the shedding of this form of IL-8. PAI-1 appears to stabilize the chemoattractant form of IL-8 at the cell surface and may represent a therapeutic target for novel anti-inflammatory strategies.
This article has been cited by other articles:
|
|
 |
|
  K. Hayashida, W. C. Parks, and P. W. Park Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines Blood, October 1, 2009; 114(14): 3033 - 3043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Masouleh, G. B. Ten Dam, M. K. Wild, R. Seelige, J. van der Vlag, A. L. Rops, F. G. Echtermeyer, D. Vestweber, T. H. van Kuppevelt, L. Kiesel, et al. Role of the Heparan Sulfate Proteoglycan Syndecan-1 (CD138) in Delayed-Type Hypersensitivity J. Immunol., April 15, 2009; 182(8): 4985 - 4993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dierker, R. Dreier, A. Petersen, C. Bordych, and K. Grobe Heparan Sulfate-modulated, Metalloprotease-mediated Sonic Hedgehog Release from Producing Cells J. Biol. Chem., March 20, 2009; 284(12): 8013 - 8022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Park, G. Liu, E. F. Lorne, X. Zhao, J. Wang, Y. Tsuruta, J. Zmijewski, and E. Abraham PAI-1 inhibits neutrophil efferocytosis PNAS, August 19, 2008; 105(33): 11784 - 11789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Patterson, A Cartwright, G David, O Fitzgerald, B Bresnihan, B A Ashton, and J Middleton Differential expression of syndecans and glypicans in chronically inflamed synovium Ann Rheum Dis, May 1, 2008; 67(5): 592 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Patrick, J. Rullo, S. Beaudin, P. Liaw, and A. E. Fox-Robichaud Hepatic leukocyte recruitment in response to time-limited expression of TNF-{alpha} and IL-1beta Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G663 - G672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Harslund, O. L. Nielsen, N. Brunner, and H. Offenberg Gender-dependent physiological implications of combined PAI-1 and TIMP-1 gene deficiency characterized in a mouse model Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1630 - R1639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Kirkpatrick and S. B. Selleck Heparan sulfate proteoglycans at a glance J. Cell Sci., June 1, 2007; 120(11): 1829 - 1832. [Full Text] [PDF]
|
|
|
|
|
|
R. Renckens, J. J. T. H. Roelofs, P. I. Bonta, S. Florquin, C. J. M. de Vries, M. Levi, P. Carmeliet, C. van't Veer, and T. van der Poll Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia Blood, February 15, 2007; 109(4): 1593 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Chung, T. G. Popova, B. A. Millis, D. V. Mukherjee, W. Zhou, L. A. Liotta, E. F. Petricoin, V. Chandhoke, C. Bailey, and S. G. Popov Secreted Neutral Metalloproteases of Bacillus anthracis as Candidate Pathogenic Factors J. Biol. Chem., October 20, 2006; 281(42): 31408 - 31418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Y. Fears, C. L. Gladson, and A. Woods Syndecan-2 Is Expressed in the Microvasculature of Gliomas and Regulates Angiogenic Processes in Microvascular Endothelial Cells J. Biol. Chem., May 26, 2006; 281(21): 14533 - 14536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.A. DeCarlo and J.M. Whitelock The Role of Heparan Sulfate and Perlecan in Bone-regenerative Procedures Journal of Dental Research, February 1, 2006; 85(2): 122 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bergheim, L. Guo, M. A. Davis, I. Duveau, and G. E. Arteel Critical Role of Plasminogen Activator Inhibitor-1 in Cholestatic Liver Injury and Fibrosis J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 592 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Taylor and R. L. Gallo Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation FASEB J, January 1, 2006; 20(1): 9 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xiao, Y.-P. Hsu, A. Ishizaka, T. Kirikae, and R. B. Moss Sputum Cathelicidin, Urokinase Plasminogen Activation System Components, and Cytokines Discriminate Cystic Fibrosis, COPD, and Asthma Inflammation Chest, October 1, 2005; 128(4): 2316 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Solic, J. Wilson, S. J. Wilson, and J. K. Shute Endothelial Activation and Increased Heparan Sulfate Expression in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 892 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Arndt, S. K. Young, and G. S. Worthen Regulation of Lipopolysaccharide-Induced Lung Inflammation by Plasminogen Activator Inhibitor-1 through a JNK-Mediated Pathway J. Immunol., September 15, 2005; 175(6): 4049 - 4059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kelly, L. J. Suva, Y. Huang, V. MacLeod, H.-Q. Miao, R. C. Walker, and R. D. Sanderson Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases Cancer Res., July 1, 2005; 65(13): 5778 - 5784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tkachenko, J. M. Rhodes, and M. Simons Syndecans: New Kids on the Signaling Block Circ. Res., March 18, 2005; 96(5): 488 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Luyendyk, W. B. Mattes, L. D. Burgoon, T. R. Zacharewski, J. F. Maddox, G. N. Cosma, P. E. Ganey, and R. A. Roth Gene Expression Analysis Points to Hemostasis in Livers of Rats Cotreated with Lipopolysaccharide and Ranitidine Toxicol. Sci., July 1, 2004; 80(1): 203 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. van Buul and P. L. Hordijk Signaling in Leukocyte Transendothelial Migration Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 824 - 833. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
